Natera, Inc.
Close on Nov 2, 2026Market cap $54.62BP/E –Yield –
Natera Total Oncology Tests Processed by Quarter
Total Oncology Tests Processed — Signatera MRD + Altera + Research (tests)
Natera Total Oncology Tests Processed: 296,700.00 tests in Q2 2026, up 57.2% from a year earlier. That is the highest of the 18 quarters on record here.
Where the Q2 2026 figure comes from
“Processed approximately 296,700 oncology tests in the second quarter of 2026, compared to approximately 188,800 in the second quarter of 2025”
Source: Form 8-K Ex 99.1 (2026-08-06) ↗
Total oncology units processed across clinical Signatera MRD, Altera comprehensive genomic profiling, and biopharma clinical trial testing.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Oncology Tests Processed — Signatera MRD + Altera + Research (tests) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 296,700.00 | +57.2% | Form 8-K Ex 99.1 (2026-08-06) ↗ |
| Q1 2026 | Mar 31, 2026 | 258,900.00 | +54.4% | Form 8-K Ex 99.1 (2026-05-07) ↗ |
| Q4 2025 | Dec 31, 2025 | 233,300.00 | +54.7% | Form 8-K Ex 99.1 (2026-02-26) ↗ |
| Q3 2025 | Sep 30, 2025 | 211,000.00 | +53.9% | Form 8-K Ex 99.1 (2025-11-06) ↗ |
| Q2 2025 | Jun 30, 2025 | 188,800.00 | +50.6% | Form 8-K Ex 99.1 (2026-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 167,700.00 | +46.1% | Form 8-K Ex 99.1 (2026-05-07) ↗ |
| Q4 2024 | Dec 31, 2024 | 150,800.00 | +54.7% | Form 8-K Ex 99.1 (2026-02-26) ↗ |
| Q3 2024 | Sep 30, 2024 | 137,100.00 | +54.4% | Form 8-K Ex 99.1 (2025-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 125,400.00 | +50.2% | Form 8-K Ex 99.1 (2025-08-07) ↗ |
| Q1 2024 | Mar 31, 2024 | 114,800.00 | +61.7% | Form 8-K Ex 99.1 (2025-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 97,500.00 | +52.3% | Form 8-K Ex 99.1 (2025-02-27) ↗ |
| Q3 2023 | Sep 30, 2023 | 88,800.00 | +67.5% | Form 8-K Ex 99.1 (2024-11-12) ↗ |
| Q2 2023 | Jun 30, 2023 | 83,500.00 | +88.9% | Form 8-K Ex 99.1 (2024-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 71,000.00 | +102.3% | Form 8-K Ex 99.1 (2024-05-09) ↗ |
| Q4 2022 | Dec 31, 2022 | 64,000.00 | – | Form 8-K Ex 99.1 (2024-02-28) ↗ |
| Q3 2022 | Sep 30, 2022 | 53,000.00 | – | Form 8-K Ex 99.1 (2023-11-08) ↗ |
| Q2 2022 | Jun 30, 2022 | 44,200.00 | – | Form 8-K Ex 99.1 (2023-08-03) ↗ |
| Q1 2022 | Mar 31, 2022 | 35,100.00 | – | Form 8-K Ex 99.1 (2023-05-09) ↗ |
Breakdown
What makes up total Oncology Tests Processed
Cite this data
StockData. (2026). Natera Total Oncology Tests Processed, quarterly Q1 2022–Q2 2026 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/vol-oncology-tests-processed
See every metric in the Natera KPI table. Data updated Nov 2, 2026.